Full-Time

Global Commercial Program Head

Director / Associate Director

Posted on 7/30/2024

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Expert

Bridgewater Township, NJ, USA

Hybrid position requiring in-office presence.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • B.S. required, Ph.D. preferred in technical discipline: engineering, science, or related field
  • Minimum 10 years of industrial biologics CMC development or manufacturing experience, CAR-T experience is highly desirable.
  • Extensive experience in cell therapy commercial cGMP program with end-to-end know-how to manage process platform changes/improvements in a global manufacturing network and change management process.
  • Candidate must have extensive experience in Cell Therapy tech transfer and/or MSAT.
  • Experience in a cross functional CMC team as a technical representative driving global programs.
  • Experience as a technical owner in reviewing regulatory submission sections, responding to agency audits.
  • Experience in implementing and managing commercial process improvements and changes.
  • Experience in driving consistency across multiple manufacturing sites.
  • Experience in Analytical Methods Transfer preferred.
  • Experience in managing external partners and CMOs preferred.
  • Extensive knowledge in process and analytical development, technology transfer, process comparability and qualification, CMC regulatory guidelines, process monitoring and analytics and manufacturing operations support.
  • Ability to think critically and demonstrated troubleshooting and problem-solving skills.
  • Results driven with strong analytical, problem solving and critical thinking skills.
  • Strong experience working in a cross-functional organization with multiple partners with competing priorities.
  • Ability to plan, multitask, prioritize and be an effective and influential decision maker focused on action and implementation.
Responsibilities
  • Represent MSAT at joint technical and CMC committees
  • Partner closely with senior leadership to achieve global alignment on all technical Carvykti scope
  • Provide technical leadership and support of an expanding global manufacturing network for best-in-class CAR-T product.
  • Work collaboratively with internal and external partners to drive global process platform improvements and cost reduction initiatives
  • Drive strategy across multiple disciplines and functions to increase robustness, drive down OOS rates and improve delivery times to patients.
  • Ensure global alignment on process platform parameters, unit operations and analytical methods at both internal and external CMO sites
  • Drive new process version plans and content for regulatory submissions
  • Ensure global records are consistent and maintained to achieve consistent performance worldwide for both Legend and partner sites.
  • Provide technical support and leadership during Agency Inspections, filing of Submissions, and IRs.
  • Maintain global master batch record and documentation on the platform process description and collaborate to the global change control process and global investigations.

Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers affecting the blood and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company focuses on personalized medicine, which means they tailor therapies to individual patients. They not only discover and develop new therapies but also bring them to market, generating revenue through licensing and sales. A notable product is their CAR-T therapy, which modifies a patient's own cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial performance and business developments.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $150M investment in Belgium facility shows commitment to expanding production capabilities.
  • Alan Bash's appointment strengthens leadership in CAR-T therapy market.
  • New R&D facility in Philadelphia focuses on next-generation cell therapies.

What critics are saying

  • Increased competition from Amgen's Imdelltra could impact market share.
  • Collaboration with Multiply Labs may face challenges in scaling up production.
  • Expansion of R&D facilities requires significant investment, potentially straining resources.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's business model includes discovery, development, and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Fierce Pharma
Mar 12th, 2025
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms.

The Yellow Brick Road
Mar 3rd, 2025
YB new stock pitches (Mon, Mar 3)

Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.

ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

INACTIVE